159 related articles for article (PubMed ID: 21112752)
41. The effects of commercial preparations of herbal supplements commonly used by women on the biotransformation of fluorogenic substrates by human cytochromes P450.
Ho SH; Singh M; Holloway AC; Crankshaw DJ
Phytother Res; 2011 Jul; 25(7):983-9. PubMed ID: 21213356
[TBL] [Abstract][Full Text] [Related]
42. Cytochrome P450 expression in human keratinocytes: an aryl hydrocarbon receptor perspective.
Swanson HI
Chem Biol Interact; 2004 Oct; 149(2-3):69-79. PubMed ID: 15501429
[TBL] [Abstract][Full Text] [Related]
43. Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction.
Matoulková P; Pávek P; Malý J; Vlček J
Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):425-35. PubMed ID: 24451000
[TBL] [Abstract][Full Text] [Related]
44. Gene expression of cytochromes P450 in liver transplants over time.
Thörn M; Lundgren S; Herlenius G; Ericzon BG; Lööf L; Rane A
Eur J Clin Pharmacol; 2004 Aug; 60(6):413-20. PubMed ID: 15197524
[TBL] [Abstract][Full Text] [Related]
45. The prediction of drug metabolism using scaffold-mediated enhancement of the induced cytochrome P450 activities in fibroblasts by hepatic transcriptional regulators.
Chiang TS; Yang KC; Zheng SK; Chiou LL; Hsu WM; Lin FH; Huang GT; Lee HS
Biomaterials; 2012 Jul; 33(21):5187-97. PubMed ID: 22541353
[TBL] [Abstract][Full Text] [Related]
46. Identification of cytochrome P450s involved in the metabolism of arachidonic acid in human platelets.
Jarrar YB; Cho SA; Oh KS; Kim DH; Shin JG; Lee SJ
Prostaglandins Leukot Essent Fatty Acids; 2013 Sep; 89(4):227-34. PubMed ID: 23932368
[TBL] [Abstract][Full Text] [Related]
47. Feed-drug interaction of orally applied butyrate and phenobarbital on hepatic cytochrome P450 activity in chickens.
Mátis G; Kulcsár A; Petrilla J; Hermándy-Berencz K; Neogrády Z
J Anim Physiol Anim Nutr (Berl); 2016 Aug; 100(4):637-42. PubMed ID: 26614344
[TBL] [Abstract][Full Text] [Related]
48. Cytochrome P450 isoforms are differently up-regulated in aflatoxin B₁-exposed human lymphocytes and monocytes.
Bahari A; Mehrzad J; Mahmoudi M; Bassami MR; Dehghani H
Immunopharmacol Immunotoxicol; 2014 Feb; 36(1):1-10. PubMed ID: 24168324
[TBL] [Abstract][Full Text] [Related]
49. End-stage renal disease reduces the expression of drug-metabolizing cytochrome P450s.
Déri MT; Kiss ÁF; Tóth K; Paulik J; Sárváry E; Kóbori L; Monostory K
Pharmacol Rep; 2020 Dec; 72(6):1695-1705. PubMed ID: 32638224
[TBL] [Abstract][Full Text] [Related]
50. SuperCYPsPred-a web server for the prediction of cytochrome activity.
Banerjee P; Dunkel M; Kemmler E; Preissner R
Nucleic Acids Res; 2020 Jul; 48(W1):W580-W585. PubMed ID: 32182358
[TBL] [Abstract][Full Text] [Related]
51. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.
Rochat B
Clin Pharmacokinet; 2005; 44(4):349-66. PubMed ID: 15828850
[TBL] [Abstract][Full Text] [Related]
52. Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters.
Weiss J; Kocher J; Mueller C; Rosenzweig S; Theile D
Biopharm Drug Dispos; 2017 Dec; 38(9):517-525. PubMed ID: 28865089
[TBL] [Abstract][Full Text] [Related]
53. Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the "rank order" approach.
Rodrigues AD
Drug Metab Lett; 2007 Jan; 1(1):31-5. PubMed ID: 19356015
[TBL] [Abstract][Full Text] [Related]
54. The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue.
Iscan M; Klaavuniemi T; Coban T; Kapucuoglu N; Pelkonen O; Raunio H
Breast Cancer Res Treat; 2001 Nov; 70(1):47-54. PubMed ID: 11767004
[TBL] [Abstract][Full Text] [Related]
55. Effect of hydrocotarnine on cytochrome P450 and P-glycoprotein.
Ito K; Kubota Y; Toda T; Suto S; Ikarashi N; Sugiyama K
Drug Metab Pharmacokinet; 2009; 24(1):108-13. PubMed ID: 19252340
[TBL] [Abstract][Full Text] [Related]
56. Up-regulation of drug-metabolizing enzyme genes in layered co-culture of a human liver cell line and endothelial cells.
Ohno M; Motojima K; Okano T; Taniguchi A
Tissue Eng Part A; 2008 Nov; 14(11):1861-9. PubMed ID: 18847370
[TBL] [Abstract][Full Text] [Related]
57. Cannabinoids and Cytochrome P450 Interactions.
Zendulka O; Dovrtělová G; Nosková K; Turjap M; Šulcová A; Hanuš L; Juřica J
Curr Drug Metab; 2016; 17(3):206-26. PubMed ID: 26651971
[TBL] [Abstract][Full Text] [Related]
58. Drug interaction potential of resveratrol.
Detampel P; Beck M; Krähenbühl S; Huwyler J
Drug Metab Rev; 2012 Aug; 44(3):253-65. PubMed ID: 22788578
[TBL] [Abstract][Full Text] [Related]
59. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions.
Yang J; Liao M; Shou M; Jamei M; Yeo KR; Tucker GT; Rostami-Hodjegan A
Curr Drug Metab; 2008 Jun; 9(5):384-94. PubMed ID: 18537575
[TBL] [Abstract][Full Text] [Related]
60. Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro.
Weiss J; Herzog M; Haefeli WE
Eur J Pharmacol; 2011 Jun; 660(2-3):298-304. PubMed ID: 21501604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
